Author’s response to reviews

Title: BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

Authors:

Wim Ceelen (wim.ceelen@ugent.be)
wouter willaert (wouter.willaert@ugent.be)
kurt van der speeten (Kurt.Vanderspeeten@zol.be)
gabriel liberale (gabriel.liberale@bordet.be)

Version: 1 Date: 15 Jul 2015

Author’s response to reviews:

Dear Editor

- I have emailed EC approval to the specified email address. The document is bilingual (Dutch-English) and specifies that the protocol is also approved by the other two participating centers (Brussels and Genk).

- We did not receive any funding, commercial or otherwise, for this study. Specifically, Roche (manufacturer of bevacizumab) is not involved in any way (and has not been approached).

- The study has been approved and is now open for inclusion (ongoing).

- The manuscript or the protocol that it describes have not been published, submitted, or presented elsewhere.

Yours,

Wim P Ceelen, on behalf of the authors